ArticleDrug and alcohol dependence2024
PrEP for people who use opioids: A NIDA clinical trials network survey study in Southern U.S. cities where HIV incidence is high.
Article in Drug and alcohol dependence, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 11 citations in OpenAlex.
- Using a Syringe Service Program-Based Community Advisory Board to Expand HIV Testing, Overdose Prevention, and PrEP Linkage in a Southern Black Neighborhood.Journal of racial and ethnic health disparities · 2026Article
- Comorbidities of substance use: Opportunities realized and future needs.Journal of substance use and addiction treatment · 2026Article
- What, how, and when matters: acceptability and preferences for HIV pre-exposure prophylaxis among people who inject drugs in New Delhi, India.AIDS and behavior · 2026Article
- Community place attachment as a significant correlate of motivation to change substance use behavior among adults who inject drugs in rural U.S.Frontiers in public health · 2026Article
- "PrEP is always on the table": mixed methods study of provider willingness to refer/link clients to PrEP in community sexual health and drug use-related programs.Journal of HIV/AIDS & social services · 2025Article
- Willingness to Take Long-Acting Injectable Preexposure Prophylaxis (PrEP) and Preference for PrEP Modalities Among People Who Inject Drugs in Washington, DC.Open forum infectious diseases · 2025Article
- Attitudes toward and experience with naloxone among people who use drugs in the Southeastern United States.The International journal on drug policy · 2025Article
- Willingness to Use Oral and Long-Acting Injectable PrEP in Substance-Using Men who have Sex with Men (SU-MSM) in High HIV Incidence Southern U.S. Cities: A NIDA Clinical Trials Network Study.AIDS and behavior · 2025Article
- HIV Prevention in Syringe Service Programs Since the Start of COVID-19: Where Do We Go From Here?Current HIV/AIDS reports · 2025Review
- Factors associated with PrEP awareness and use among men who have sex with men who use drugs in the Southern United States.AIDS care · 2025Article
- Program Director Reports of COVID-19 Lockdown-Driven Service Changes in Community-Based STI Clinics and Syringe Services Programs in the Southeastern U.S.AIDS education and prevention : official publication of the International Society for AIDS Education · 2024Article
- Integrating harm reduction and addiction care in HIV prevention among persons who inject drugs in the United States-a narrative review.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 12 institutions in 1 country.
Funding
Abstract
backgroundPeople who use opioids (PWUO) are at increased risk for HIV. Pre-exposure prophylaxis (PrEP) is effective but underutilized as HIV prevention among PWUO. This study examined predictors of willingness to take daily oral PrEP and long-acting injectable (LAI) PrEP among PWUO across eight Southern urban cities with high HIV incidence.
methodsHIV-negative PWUO (N = 308) seeking services in community-based programs participated in this cross-sectional survey study. Measures included demographics, sexual risk behavior, substance use frequency, and awareness of and willingness to take oral and injectable PrEP. Data were analyzed using mixed-effects models.
resultsWillingness to take daily oral and LAI PrEP was moderately high (69.16% and 62.02%, respectively). Half had heard of PrEP, but only 4% had ever taken it. Only education and condomless vaginal sex predicted willingness to take oral PrEP. Only education predicted willingness to take LAI PrEP. Polysubstance use was prevalent, with substantial proportions of PWUO reporting frequent use of injection drugs (opioids or stimulants, 79.5%), non-injection opioids (73.3%), non-injection stimulants (71.1%), cannabis (62.6%), and hazardous drinking (29.6%). About 20% reported past-year condomless anal sex, and one-third reported past-year condomless vaginal sex.
conclusionsPWUO in this study were amenable to PrEP, particularly in light of education and condomless vaginal sex. Careful consideration for matching PrEP messaging to the PWUO audience is needed. PrEP promotion should expand beyond men who have sex with men to include groups such as these predominantly heterosexual, polysubstance-using PWUO with HIV risk who were open to both formulations of PrEP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.